Froedtert and the Medical College of Wisconsin Trials

Froedtert and the Medical College of Wisconsin	Welcome, Profile Billing Logout

901 Trials

Active Trials

12 3 4 5 6 7 8 9 10 »

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Evans, Douglas B

PCDC, NCT06388967: Pancreatic Cancer Detection Consortium

Recruiting

N/A

2000

Japan, US, RoW

PANcreatic cancer Exosome Early detectiON (PANXEON), PANXEON (PANcreatic cancer Exosome Early detectiON)

City of Hope Medical Center

Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Stage I, Pancreatic Cancer Stage, Pancreatic Cancer Resectable, Pancreatic Cancer Stage 0, Pancreatic Cancer Stage II, Pancreatic Cancer Stage III, Pancreatic Cancer, Adult, Pancreatic Cancer Non-resectable

11/25

PROTECT-PANC, NCT06228599: Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

Recruiting

N/A

Treatment Plan

Medical College of Wisconsin

Pancreas Cancer

07/26

Sorror, Mohamed

NCT03870750: Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Active, not recruiting

2/3

455

Supportive Palliative Care, Comfort Care, palliation, palliative care, palliative therapy, Palliative Treatment, Symptom Management, Symptoms Management, PA-Palliative Therapy, Clinical Management, Best Practice, standard of care, standard therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment, Survey Administration

Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)

Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder

12/25

BMT CTN 1704, NCT03992352: Composite Health Assessment Risk Model (CHARM) for Older Adults

Completed

N/A

1229

Age 60+ with planned HCT for Hematologic Malignancy

Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program

Hematologic Malignancy

05/23

NAVIGATE, NCT06472128: Novel Digital Application for Patients With Acute Leukemia

Recruiting

N/A

200

DREAMLAND, VITAL WELLNESS

Massachusetts General Hospital, National Cancer Institute (NCI)

Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

04/29

04/30

SCOPE-L, NCT05237258: Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Recruiting

N/A

2300

Specialty Palliative Care, Primary Palliative Care

Massachusetts General Hospital, Patient-Centered Outcomes Research Institute

Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

04/28

04/29

Wong, Stuart J

TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Recruiting

100

Canada, US

Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin

Coherus Biosciences, Inc.

Nasopharyngeal Cancer Recurrent

12/27

NCT03811015: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Suspended

636

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

National Cancer Institute (NCI)

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

01/27

NRG-HN009, NCT05050162: Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Recruiting

2/3

1714

Europe, Canada, US, RoW

Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

NRG Oncology, National Cancer Institute (NCI)

Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8

02/26

TRYHARD, NCT01711658: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Completed

142

Canada, US

IMRT, Cisplatin, placebo, Lapatinib

Radiation Therapy Oncology Group, GlaxoSmithKline, Novartis

Non-HPV Locally Advanced Head and Neck Cancer

12/20

09/22

NCT04752384: Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

Completed

Buprenorphine, Belbuca, Probuphine, Buprenex, Tramadol, Ultram, Ryzolt, ConZip, Oral Mucositis (OM) Pain App, OM Pain App

Medical College of Wisconsin

Head and Neck Squamous Cell Carcinoma

04/24

NCT04671667: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting

188

Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam

National Cancer Institute (NCI)

Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma

02/26

NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn

130

Europe, US, RoW

RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab

Replimune Inc., Bristol-Myers Squibb

Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

03/26

06/26

GALAXIES H&N-202, NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck-

Recruiting

360

Europe, Canada, Japan, US, RoW

Dostarlimab, Belrestotug, Nelistotug, GSK4381562

GlaxoSmithKline, iTeos Therapeutics

Neoplasms, Head and Neck

05/27

KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting

102

Canada, US

Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT

RTOG Foundation, Inc., Merck Sharp & Dohme LLC

Head and Neck Squamous Cell Carcinoma (HNSCC)

07/27

07/29

NRG-HN010, NCT05408845: Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting

146

Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate

NRG Oncology, National Cancer Institute (NCI)

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma

07/28

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

NCT03459729: Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

Completed

Antitumor B, Zeng Sheng Ping, ATB, ACAPHA

Medical College of Wisconsin, National Cancer Institute (NCI)

Squamous Cell Carcinoma of the Oral Cavity

02/22

NCT04278989: Inhibition of Oral Tumorigenesis by Antitumor B

Recruiting

Anti-tumor B, Zeng-Sheng-Ping, ACAPHA, ATB

Medical College of Wisconsin

Squamous Cell Cancer of the Oral Cavity

03/25

NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Terminated

HB-201 IV

Hookipa Biotech GmbH

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

11/23

NCT05452408: Antitumor-B KAC PK Study

Withdrawn

Antitumor B KAC

Medical College of Wisconsin

Squamous Cell Carcinoma of the Oral Cavity

12/27

NCT02727062: Smartphone Pain App for Assessing Oral Mucositis Pain in Patients

Terminated

N/A

OM Pain App, Accelerometer

Stuart Wong

Oral Mucositis

08/19

Thompson, Jonathan

ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting

1210

US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation Activity, Observation, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration

National Cancer Institute (NCI)

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8

12/25

NCT04181060: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Recruiting

300

Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib

National Cancer Institute (NCI)

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

12/26

EA5181, NCT04092283: Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Active, not recruiting

660

US, RoW

Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt

National Cancer Institute (NCI)

Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma

12/28

POETIC-A, NCT04584853 / 2019-003897-24: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

Recruiting

2032

Europe

Abemaciclib, Verzenios, Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen), Arimidex, Aromasin, Femara, or Tamoxifen

Institute of Cancer Research, United Kingdom

Breast Cancer Female

09/30

03/32

stAAAble, NCT06001918: Nectero EAST System Clinical Study

Suspended

2/3

400

US, RoW

Nectero EAST System

Nectero Medical, Inc.

Abdominal Aortic Aneurysm

03/27

12/29

RAPTOR, NCT04402788: Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The Trial

Recruiting

2/3

138

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

National Cancer Institute (NCI), NRG Oncology

Extensive Stage Lung Small Cell Carcinoma

04/27

Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting

2/3

10000

Screening Platform

SWOG Cancer Research Network, National Cancer Institute (NCI)

Previously Treated Non-Small Cell Lung Cancer

01/29

NCT04533451: Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Active, not recruiting

101

Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

10/23

05/27

NCT06305715: Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Recruiting

Radiation Therapy, Targeted TKI therapy

Medical College of Wisconsin

Non Small Cell Lung Cancer

06/27

06/28

BT5528-100, NCT04180371 / 2019-003653-29: Study in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting

1/2

288

Europe, US, RoW

BT5528, Nivolumab, Opdivo

BicycleTx Limited

Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer

10/25

HPN328-4001, NCT04471727: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/)

Recruiting

1/2

232

Gocatamig, HPN328, MK-6070, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo

Small-Cell Lung Cancer, Neuroendocrine Carcinoma

11/27

DUET-1, NCT05120271 / 2021-005086-41: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Recruiting

1/2

110

Europe, US

CAR-GPC3 T Cells, BOXR1030

Sotio Biotech Inc., SOTIO Biotech AG, SOTIO Biotech a.s.

Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma

10/27

12/42

KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting

1/2

333

INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2

Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC

Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma

02/26

05/26

NCT06069934: Pridopidine Expanded Access Program

Available

N/A

Pridopidine

Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)

Amyotrophic Lateral Sclerosis

ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Active, not recruiting

N/A

8300

US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography Test, EC, Echocardiography, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

National Cancer Institute (NCI)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8

09/26

Fenske, Timothy

NCT04212013: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Active, not recruiting

Ibrutinib, Rituximab, Placebo

Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.

Marginal Zone Lymphoma

03/27

EA4151, NCT03267433: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Active, not recruiting

689

US, RoW

Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Mantle Cell Lymphoma

01/27

NCT05976763: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Recruiting

421

Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, PET, Computed Tomography, CAT Scan, CT Scan, Magnetic Resonance Imaging, MRI, Esophagogastroduodenoscopy, EGD, Colonoscopy, Biospecimen Collection, Questionnaire Administration

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Mantle Cell Lymphoma

08/38

EA4181, NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting

360

Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Liver Lymphoma, Mantle Cell Lymphoma

12/25

Schneider, Bryan

BRE12-158, NCT02101385: Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Completed

193

Genomically Directed Monotherapy, Observation/Standard Therapy

Bryan Schneider, MD, Hoosier Cancer Research Network, Vera Bradley Foundation for Breast Cancer, Walther Cancer Institute, Strategic Research Initiative Grant through IUSCC

Malignant Neoplasm of Breast, Breast Cancer

02/21

09/22

ECOG-ACRIN EAZ171, NCT04001829: Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Active, not recruiting

249

Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8

09/23

03/27

NCT04534283: A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Terminated

Abemaciclib, LY2835219, LY3214996

Anita Turk, Eli Lilly and Company

Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation

08/23

PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting

197

Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077

Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research

Breast Cancer, Triple Negative Breast Cancer

01/29

01/34

NCT03896815: Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

No Longer Available

N/A

INCB054329

Incyte Corporation

EDPO, NCT06081517: Evaluating Disparities in Precision Oncology

Recruiting

N/A

10600

Social Determinants of Health and toxicity questionnaires

Indiana University

Metastatic Cancer, Advanced Cancer

12/28

NCT02610426: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Recruiting

N/A

162

Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Breast Carcinoma

01/00

NCT02610413: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Recruiting

N/A

354

Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Breast Carcinoma

01/00

NCT02610439: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Recruiting

N/A

575

Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Breast Carcinoma, Neuropathy

01/00

George, Ben

GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting

2/3

700

GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin

Gritstone bio, Inc.

Colorectal Neoplasms

03/27

SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting

Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol

Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic

Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma

06/25

12/25

SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated

Europe, Canada, US

Autologous genetically modified ADP-A2M4CD8 cells

Adaptimmune, ICON plc

Esophageal Cancer, Esophagogastric Junction Cancer

06/23

12/23

AIRPanc, NCT06048484: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting

Stereotactic body radiotherapy (SBRT), Zimberelimab, AB122, Quemliclustat, AB680, Etrumadenant, AB928, Modified FOLFIRINOX, mFOLFIRINOX

Gulam Manji, Arcus Biosciences, Inc.

Pancreatic Ductal Adenocarcinoma

04/27

AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruiting

1/2

158

ELI-002 7P

Elicio Therapeutics

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S

11/26

MCW I-PREDICT, NCT05674825: Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Recruiting

1/2

400

Targeted agent, Standard of care agent

Medical College of Wisconsin

Cancer

06/27

01/31

NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

Terminated

US, RoW

GNX102

GlycoNex, Inc.

Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm

07/23

NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Terminated

TP-1287

Sumitomo Pharma America, Inc.

Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma

01/24

TRACT DNA, NCT05067842: Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma

Recruiting

N/A

Circulating tumor DNA(ctDNA) level measurement

Medical College of Wisconsin

Adenocarcinoma Esophagus

06/31

06/34

Thakar, Monica S

STIR Trial, NCT02100891: Phase 2 Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

Terminated

Allogeneic HCT, Haplo transplant, Reduced-intensity conditioning, Bone marrow transplant, Donor NK Cell Infusion, Natural Killer Cells, Adoptive immunotherapy, Donor Lymphocyte Infusion, IND 13794

Monica Thakar

Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, CNS Tumors

06/20

07/20

Truwit, Jonathon

NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting

274

Europe, US, RoW

DAS181, Placebo, DAS181 COVID-19, DAS181 OL

Ansun Biopharma, Inc.

Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19

08/25

Salit, Rachel

P30CA015704, NCT02251821: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, allogeneic stem cell transplantation, HSC, HSCT, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Mycophenolate Mofetil, Cellcept, MMF, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Jakafi, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation, SCT_TBI, Umbilical Cord Blood Transplantation, Cord Blood Transplantation, UCB transplantation

Fred Hutchinson Cancer Center, Incyte Corporation, National Cancer Institute (NCI)

Primary Myelofibrosis, Secondary Myelofibrosis

12/22

12/25

NCT04370301: Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting

Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, JAK Inhibitor, JAK inhibitors, Janus Kinase Inhibitor, Ruxolitinib, Fedratinib, Fludarabine, Fluradosa, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, 143011-72-7, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, FK-506, Tacforius, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, Total-Body Irradiation Prior to Stem Cell Transplant, SCT_TBI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Magnetic Resonance Imaging, MR Imaging, MRI, Bone Marrow Biopsy, Biopsy of Bone Marrow, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

Fred Hutchinson Cancer Center

Primary Myelofibrosis, Secondary Myelofibrosis

08/26

08/29

NCT06752694: Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Marrow Transplantation, Blood and Bone Marrow Transplant, BMT, Bone Marrow, Bone Marrow Grafting, Bone Marrow Transplant, Marrow Transplantation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclosporine, 27-400, Ciclosporin, CsA, CyA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Fludarabine, Fluradosa, Granulocyte Colony-Stimulating Factor, Colony Stimulating Factor 3, Colony-Stimulating Factor (Granulocyte), Colony-Stimulating Factor 3, CSF3, G CSF, G-CSF, GCSF, Granulocyte Colony Stimulating Factor, Pluripoietin, Mycophenolate Mofetil, CellCept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Ruxolitinib, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, AY-22989, AY22989, RAPA, Rapamune, Rapamycin, SILA 9268A, SILA-9268A, SILA9268A, WY 090217, WY-090217, WY090217, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation, Multigated Acquisition Scan, MUGA, MUGA Scan, Radionuclide ventriculography, Echocardiography, EC

Fred Hutchinson Cancer Center, Incyte Corporation

Aplastic Anemia

06/27

NCI-2020-01626, NCT04384692: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Jylamvo, Mycophenolate Mofetil, CellCept, MMF, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, Total-Body Irradiation Prior to Stem Cell Transplant, Computed Tomography, CAT Scan, Computed Axial Tomography, Echocardiography, EC, Bone Marrow Aspiration and Biopsy, Magnetic Resonance Imaging, MRI, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging

Fred Hutchinson Cancer Center

Primary Myelofibrosis, Secondary Myelofibrosis

12/25

12/29

Yoon, Harry H

NCT03396471: Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Terminated

Pembrolizumab, Keytruda, External Beam Radiation Therapy, External Beam Radiation Therapy (EBRT)

Hoosier Cancer Research Network, Merck Sharp & Dohme LLC

Carcinoma, Unspecified Site

08/21

03/23

SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting

Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol

Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic

Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma

06/25

12/25

NCT02730546: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Completed

1/2

Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, RADIATION, Radiotherapeutics, radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery

Mayo Clinic, National Cancer Institute (NCI)

Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7

07/21

10/23

ELIMYN18.2, NCT04404595: Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Active, not recruiting

1/2

110

Canada, US

CT041

CARsgen Therapeutics Co., Ltd.

Gastric Cancer, Pancreatic Cancer

06/25

09/35

Bradley, William H

UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated

Canada, US, RoW

Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo

Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

09/23

NRG-GY026, NCT05256225: Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Recruiting

360

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Survey Administration, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk

National Cancer Institute (NCI), NRG Oncology

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Carcinosarcoma

10/27

TETON, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting

Canada, US, RoW

ZN-c3, azenosertib, KP-2638

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Uterine Serous Carcinoma

11/24

05/25

EndoBARR, NCT03694262: The Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed

Rucaparib, Rubraca, Bevacizumab, Avastin, Atezolizumab, Tecentriq

Medical College of Wisconsin, Genentech, Inc., Clovis Oncology, Inc.

Endometrial Cancer, Uterine Carcinosarcoma

03/23

04/23

NCT06388018: Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer

Recruiting

325

Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, High-Dose-Rate Vaginal Brachytherapy, HDR-IVB, High-Dose-Rate Intra-Vaginal Brachytherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

NRG Oncology, National Cancer Institute (NCI)

Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8

01/27

CCTG EN10, NCT05640999: Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Recruiting

393

Europe, Canada, US, RoW

Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation

Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network

Endometrial Cancer

12/28

06/29

OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

	Presentation of OVATION 2 data in advanced ovarian cancer
	Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer

Active, not recruiting

1/2

130

Canada, US

IMNN-001, Carboplatin, Paclitaxel

Imunon

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

07/24

11/25

ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting

1/2

390

ACR-368, prexasertib, Gemcitabine, OncoSignature

Acrivon Therapeutics, GOG Foundation

Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma

07/26

12/27

NRG-GY027, NCT05276973: Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Active, not recruiting

Biopsy, BIOPSY_TYPE, Bx, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

National Cancer Institute (NCI), NRG Oncology

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Fallopian Tube High Grade Serous Adenocarcinoma, Unresectable Ovarian Endometrioid Adenocarcinoma, Unresectable Ovarian High Grade Serous Adenocarcinoma, Unresectable Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma

01/25

02/26

NRG-GY022, NCT03997370: Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Recruiting

350

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Iohexol, Omnipaque

NRG Oncology, National Cancer Institute (NCI)

Malignant Solid Neoplasm

02/27

02/28

NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Terminated

HB-201 IV

Hookipa Biotech GmbH

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

11/23

NRG-GY031, NCT05950464: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recruiting

BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Electrocardiography, ECG, EKG, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Tuvusertib, ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI), NRG Oncology

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Low Grade Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Low Grade Endometrioid Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma

04/26

SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting

N/A

2262

Canada, US, RoW

Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US

NRG Oncology, National Cancer Institute (NCI)

Ovarian Carcinoma

06/36

06/37

Talano, Julie-An M

NCT02600208: Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

Active, not recruiting

2/3

CliniMACs, Alpha/Beta T-Cell Depletion

Julie-An M. Talano, Miltenyi Biotec, Inc.

Hematologic Malignancies

12/26

NCT04746209: Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

Recruiting

Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab, Blincyto

Medical College of Wisconsin, Amgen, University of Wisconsin, Madison

B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood

02/24

12/29

CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting

Canada, US

Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS

Center for International Blood and Marrow Transplant Research

SCID

08/29

08/30

NCT03980769: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Recruiting

Thiotepa, 1,1',1"-phosphinothioylidynetrisaziridine, N,N', N''-Triethylenethiophosphoramid, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Triethylene thiophosphoramide, Triethylenethiophosphoramide, TSPA, Treosulfan, (S-(R*,R*))-1,2,3,4-butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-, 299-75-2, 39069, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon, Fludarabine Phosphate, 2-F-ara-AMP, 312887, 328002, 75607-67-9, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Fludarabine-5'-Monophosphate, Rabbit Anti-Thymocyte Globulin, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Bone Marrow Biopsy, Bone Marrow Aspiration, Magnetic Resonance Imaging, MRI, MRI Scan, Biospecimen Collection

Fred Hutchinson Cancer Center

Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

07/27

CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL

Active, not recruiting

121

Europe, Canada, US

CTL019

Novartis Pharmaceuticals, Children's Oncology Group

B-Cell Acute Lymphoblastic Leukemia

10/27

NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting

1/2

Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16

St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach

Hemophagocytic Lymphohistiocytosis

08/25

08/26

CAR-20/19-T, NCT04049383: Cells in Patients With Relapsed/Refractory B Cell ALL

Suspended

CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells

Medical College of Wisconsin, Children's Hospital and Health System Foundation, Wisconsin

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia

06/25

06/26

NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available

N/A

Canada, US, RoW

CTL019, tisagenlecleucel, Kymriah

Novartis Pharmaceuticals

Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)

MA, Wen Wee

eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting

250

Europe, Canada, Japan, US, RoW

zenocutuzumab (MCLA-128), bispecific, MCLA-128

Partner Therapeutics, Inc.

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

12/26

NCT04390243: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Terminated

Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818

Academic and Community Cancer Research United, National Cancer Institute (NCI)

Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

11/23

Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting

350

Europe, Canada, US

9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar

Actuate Therapeutics Inc., Actuate Therapeutics Inc

Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma

01/25

01/26

ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting

122

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080

Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.

Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma

12/24

12/26

NCT03337087: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active, not recruiting

1/2

Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Sucrosofate, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Rucaparib, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-, 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one

Academic and Community Cancer Research United, National Cancer Institute (NCI)

Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7

03/21

08/25

ELU-FRÎ±-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated

1/2

ELU001, FA-CDC

Elucida Oncology

Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer

06/24

COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Active, not recruiting

1/2

Europe, Canada, US, RoW

TAK-280

Takeda, Takeda Development Center Americas, Inc.

Unresectable Locally Advanced or Metastatic Cancer

06/25

KEYNOTE-G08, NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors

Recruiting

1/2

358

US, RoW

GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), ENHERTU®, pembrolizumab, KEYTRUDA®

GI Innovation, Inc., Merck Sharp & Dohme LLC

Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)

11/25

04/27

NCT06608940: BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Not yet recruiting

1/2

BC3402, Durvalumab, Tremelimumab

Case Comprehensive Cancer Center

Hepato Cellular Carcinoma (HCC)

01/27

01/28

KEYNOTE-E06, NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

	Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
	Sep 2021 - Sep 2021: Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO

Terminated

Oraxol, oral HM30181A + oral paclitaxel, Pembrolizumab, Keytruda

Athenex, Inc., Merck Sharp & Dohme LLC

Solid Tumor

05/23

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Evans, Douglas B

PCDC, NCT06388967: Pancreatic Cancer Detection Consortium

Recruiting

N/A

2000

Japan, US, RoW

PANcreatic cancer Exosome Early detectiON (PANXEON), PANXEON (PANcreatic cancer Exosome Early detectiON)

City of Hope Medical Center

11/25

PROTECT-PANC, NCT06228599: Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

Recruiting

N/A

Treatment Plan

Medical College of Wisconsin

Pancreas Cancer

07/26

Sorror, Mohamed

NCT03870750: Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Active, not recruiting

2/3

455

Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)

Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder

12/25

BMT CTN 1704, NCT03992352: Composite Health Assessment Risk Model (CHARM) for Older Adults

Completed

N/A

1229

Age 60+ with planned HCT for Hematologic Malignancy

Hematologic Malignancy

05/23

NAVIGATE, NCT06472128: Novel Digital Application for Patients With Acute Leukemia

Recruiting

N/A

200

DREAMLAND, VITAL WELLNESS

Massachusetts General Hospital, National Cancer Institute (NCI)

Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

04/29

04/30

SCOPE-L, NCT05237258: Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Recruiting

N/A

2300

Specialty Palliative Care, Primary Palliative Care

Massachusetts General Hospital, Patient-Centered Outcomes Research Institute

Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

04/28

04/29

Wong, Stuart J

TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Recruiting

100

Canada, US

Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin

Coherus Biosciences, Inc.

Nasopharyngeal Cancer Recurrent

12/27

NCT03811015: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Suspended

636

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

National Cancer Institute (NCI)

01/27

NRG-HN009, NCT05050162: Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Recruiting

2/3

1714

Europe, Canada, US, RoW

NRG Oncology, National Cancer Institute (NCI)

02/26

TRYHARD, NCT01711658: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Completed

142

Canada, US

IMRT, Cisplatin, placebo, Lapatinib

Radiation Therapy Oncology Group, GlaxoSmithKline, Novartis

Non-HPV Locally Advanced Head and Neck Cancer

12/20

09/22

NCT04752384: Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

Completed

Buprenorphine, Belbuca, Probuphine, Buprenex, Tramadol, Ultram, Ryzolt, ConZip, Oral Mucositis (OM) Pain App, OM Pain App

Medical College of Wisconsin

Head and Neck Squamous Cell Carcinoma

04/24

Recruiting

188

Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam

National Cancer Institute (NCI)

02/26

NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn

130

Europe, US, RoW

RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab

Replimune Inc., Bristol-Myers Squibb

Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

03/26

06/26

Recruiting

360

Europe, Canada, Japan, US, RoW

Dostarlimab, Belrestotug, Nelistotug, GSK4381562

GlaxoSmithKline, iTeos Therapeutics

Neoplasms, Head and Neck

05/27

KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting

102

Canada, US

Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT

RTOG Foundation, Inc., Merck Sharp & Dohme LLC

Head and Neck Squamous Cell Carcinoma (HNSCC)

07/27

07/29

Recruiting

146

NRG Oncology, National Cancer Institute (NCI)

07/28

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

NCT03459729: Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

Completed

Antitumor B, Zeng Sheng Ping, ATB, ACAPHA

Medical College of Wisconsin, National Cancer Institute (NCI)

Squamous Cell Carcinoma of the Oral Cavity

02/22

NCT04278989: Inhibition of Oral Tumorigenesis by Antitumor B

Recruiting

Anti-tumor B, Zeng-Sheng-Ping, ACAPHA, ATB

Medical College of Wisconsin

Squamous Cell Cancer of the Oral Cavity

03/25

NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Terminated

HB-201 IV

Hookipa Biotech GmbH

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

11/23

NCT05452408: Antitumor-B KAC PK Study

Withdrawn

Antitumor B KAC

Medical College of Wisconsin

Squamous Cell Carcinoma of the Oral Cavity

12/27

NCT02727062: Smartphone Pain App for Assessing Oral Mucositis Pain in Patients

Terminated

N/A

OM Pain App, Accelerometer

Stuart Wong

Oral Mucositis

08/19

Thompson, Jonathan

ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting

1210

US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation Activity, Observation, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration

National Cancer Institute (NCI)

12/25

NCT04181060: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Recruiting

300

Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib

National Cancer Institute (NCI)

12/26

Active, not recruiting

660

US, RoW

National Cancer Institute (NCI)

12/28

POETIC-A, NCT04584853 / 2019-003897-24: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

Recruiting

2032

Europe

Abemaciclib, Verzenios, Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen), Arimidex, Aromasin, Femara, or Tamoxifen

Institute of Cancer Research, United Kingdom

Breast Cancer Female

09/30

03/32

stAAAble, NCT06001918: Nectero EAST System Clinical Study

Suspended

2/3

400

US, RoW

Nectero EAST System

Nectero Medical, Inc.

Abdominal Aortic Aneurysm

03/27

12/29

RAPTOR, NCT04402788: Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The Trial

Recruiting

2/3

138

National Cancer Institute (NCI), NRG Oncology

Extensive Stage Lung Small Cell Carcinoma

04/27

Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting

2/3

10000

Screening Platform

SWOG Cancer Research Network, National Cancer Institute (NCI)

Previously Treated Non-Small Cell Lung Cancer

01/29

NCT04533451: Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Active, not recruiting

101

Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

10/23

05/27

NCT06305715: Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Recruiting

Radiation Therapy, Targeted TKI therapy

Medical College of Wisconsin

Non Small Cell Lung Cancer

06/27

06/28

BT5528-100, NCT04180371 / 2019-003653-29: Study in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting

1/2

288

Europe, US, RoW

BT5528, Nivolumab, Opdivo

BicycleTx Limited

10/25

HPN328-4001, NCT04471727: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/)

Recruiting

1/2

232

Gocatamig, HPN328, MK-6070, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo

Small-Cell Lung Cancer, Neuroendocrine Carcinoma

11/27

DUET-1, NCT05120271 / 2021-005086-41: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Recruiting

1/2

110

Europe, US

CAR-GPC3 T Cells, BOXR1030

Sotio Biotech Inc., SOTIO Biotech AG, SOTIO Biotech a.s.

Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma

10/27

12/42

KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting

1/2

333

Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC

Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma

02/26

05/26

NCT06069934: Pridopidine Expanded Access Program

Available

N/A

Pridopidine

Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)

Amyotrophic Lateral Sclerosis

ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Active, not recruiting

N/A

8300

US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography Test, EC, Echocardiography, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

National Cancer Institute (NCI)

09/26

Fenske, Timothy

NCT04212013: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Active, not recruiting

Ibrutinib, Rituximab, Placebo

Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.

Marginal Zone Lymphoma

03/27

EA4151, NCT03267433: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Active, not recruiting

689

US, RoW

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Mantle Cell Lymphoma

01/27

NCT05976763: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Recruiting

421

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Mantle Cell Lymphoma

08/38

EA4181, NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting

360

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Liver Lymphoma, Mantle Cell Lymphoma

12/25

Schneider, Bryan

BRE12-158, NCT02101385: Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Completed

193

Genomically Directed Monotherapy, Observation/Standard Therapy

Bryan Schneider, MD, Hoosier Cancer Research Network, Vera Bradley Foundation for Breast Cancer, Walther Cancer Institute, Strategic Research Initiative Grant through IUSCC

Malignant Neoplasm of Breast, Breast Cancer

02/21

09/22

ECOG-ACRIN EAZ171, NCT04001829: Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Active, not recruiting

249

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

09/23

03/27

NCT04534283: A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Terminated

Abemaciclib, LY2835219, LY3214996

Anita Turk, Eli Lilly and Company

Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation

08/23

PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting

197

Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077

Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research

Breast Cancer, Triple Negative Breast Cancer

01/29

01/34

NCT03896815: Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

No Longer Available

N/A

INCB054329

Incyte Corporation

EDPO, NCT06081517: Evaluating Disparities in Precision Oncology

Recruiting

N/A

10600

Social Determinants of Health and toxicity questionnaires

Indiana University

Metastatic Cancer, Advanced Cancer

12/28

NCT02610426: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Recruiting

N/A

162

Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Breast Carcinoma

01/00

NCT02610413: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Recruiting

N/A

354

Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Breast Carcinoma

01/00

NCT02610439: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Recruiting

N/A

575

Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Breast Carcinoma, Neuropathy

01/00

George, Ben

GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting

2/3

700

GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin

Gritstone bio, Inc.

Colorectal Neoplasms

03/27

SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting

Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol

Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic

Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma

06/25

12/25

SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated

Europe, Canada, US

Autologous genetically modified ADP-A2M4CD8 cells

Adaptimmune, ICON plc

Esophageal Cancer, Esophagogastric Junction Cancer

06/23

12/23

AIRPanc, NCT06048484: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting

Stereotactic body radiotherapy (SBRT), Zimberelimab, AB122, Quemliclustat, AB680, Etrumadenant, AB928, Modified FOLFIRINOX, mFOLFIRINOX

Gulam Manji, Arcus Biosciences, Inc.

Pancreatic Ductal Adenocarcinoma

04/27

AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruiting

1/2

158

ELI-002 7P

Elicio Therapeutics

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S

11/26

MCW I-PREDICT, NCT05674825: Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Recruiting

1/2

400

Targeted agent, Standard of care agent

Medical College of Wisconsin

Cancer

06/27

01/31

NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

Terminated

US, RoW

GNX102

GlycoNex, Inc.

Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm

07/23

NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Terminated

TP-1287

Sumitomo Pharma America, Inc.

Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma

01/24

TRACT DNA, NCT05067842: Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma

Recruiting

N/A

Circulating tumor DNA(ctDNA) level measurement

Medical College of Wisconsin

Adenocarcinoma Esophagus

06/31

06/34

Thakar, Monica S

STIR Trial, NCT02100891: Phase 2 Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

Terminated

Allogeneic HCT, Haplo transplant, Reduced-intensity conditioning, Bone marrow transplant, Donor NK Cell Infusion, Natural Killer Cells, Adoptive immunotherapy, Donor Lymphocyte Infusion, IND 13794

Monica Thakar

Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, CNS Tumors

06/20

07/20

Truwit, Jonathon

NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting

274

Europe, US, RoW

DAS181, Placebo, DAS181 COVID-19, DAS181 OL

Ansun Biopharma, Inc.

Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19

08/25

Salit, Rachel

P30CA015704, NCT02251821: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting

Fred Hutchinson Cancer Center, Incyte Corporation, National Cancer Institute (NCI)

Primary Myelofibrosis, Secondary Myelofibrosis

12/22

12/25

NCT04370301: Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting

Fred Hutchinson Cancer Center

Primary Myelofibrosis, Secondary Myelofibrosis

08/26

08/29

NCT06752694: Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting

Fred Hutchinson Cancer Center, Incyte Corporation

Aplastic Anemia

06/27

NCI-2020-01626, NCT04384692: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Recruiting

Fred Hutchinson Cancer Center

Primary Myelofibrosis, Secondary Myelofibrosis

12/25

12/29

Yoon, Harry H

NCT03396471: Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Terminated

Pembrolizumab, Keytruda, External Beam Radiation Therapy, External Beam Radiation Therapy (EBRT)

Hoosier Cancer Research Network, Merck Sharp & Dohme LLC

Carcinoma, Unspecified Site

08/21

03/23

SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting

Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol

Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic

Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma

06/25

12/25

Completed

1/2

Mayo Clinic, National Cancer Institute (NCI)

07/21

10/23

ELIMYN18.2, NCT04404595: Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Active, not recruiting

1/2

110

Canada, US

CT041

CARsgen Therapeutics Co., Ltd.

Gastric Cancer, Pancreatic Cancer

06/25

09/35

Bradley, William H

UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated

Canada, US, RoW

Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo

Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

09/23

NRG-GY026, NCT05256225: Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Recruiting

360

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Survey Administration, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk

National Cancer Institute (NCI), NRG Oncology

10/27

TETON, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting

Canada, US, RoW

ZN-c3, azenosertib, KP-2638

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Uterine Serous Carcinoma

11/24

05/25

EndoBARR, NCT03694262: The Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed

Rucaparib, Rubraca, Bevacizumab, Avastin, Atezolizumab, Tecentriq

Medical College of Wisconsin, Genentech, Inc., Clovis Oncology, Inc.

Endometrial Cancer, Uterine Carcinosarcoma

03/23

04/23

NCT06388018: Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer

Recruiting

325

NRG Oncology, National Cancer Institute (NCI)

Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8

01/27

CCTG EN10, NCT05640999: Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Recruiting

393

Europe, Canada, US, RoW

Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation

Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network

Endometrial Cancer

12/28

06/29

OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

	Presentation of OVATION 2 data in advanced ovarian cancer
	Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer

Active, not recruiting

1/2

130

Canada, US

IMNN-001, Carboplatin, Paclitaxel

Imunon

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

07/24

11/25

ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting

1/2

390

ACR-368, prexasertib, Gemcitabine, OncoSignature

Acrivon Therapeutics, GOG Foundation

Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma

07/26

12/27

NRG-GY027, NCT05276973: Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Active, not recruiting

National Cancer Institute (NCI), NRG Oncology

01/25

02/26

NRG-GY022, NCT03997370: Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Recruiting

350

NRG Oncology, National Cancer Institute (NCI)

Malignant Solid Neoplasm

02/27

02/28

NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Terminated

HB-201 IV

Hookipa Biotech GmbH

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

11/23

NRG-GY031, NCT05950464: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recruiting

BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Electrocardiography, ECG, EKG, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Tuvusertib, ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI), NRG Oncology

04/26

SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting

N/A

2262

Canada, US, RoW

NRG Oncology, National Cancer Institute (NCI)

Ovarian Carcinoma

06/36

06/37

Talano, Julie-An M

NCT02600208: Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

Active, not recruiting

2/3

CliniMACs, Alpha/Beta T-Cell Depletion

Julie-An M. Talano, Miltenyi Biotec, Inc.

Hematologic Malignancies

12/26

NCT04746209: Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

Recruiting

Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab, Blincyto

Medical College of Wisconsin, Amgen, University of Wisconsin, Madison

B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood

02/24

12/29

CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting

Canada, US

Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS

Center for International Blood and Marrow Transplant Research

SCID

08/29

08/30

NCT03980769: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Recruiting

Fred Hutchinson Cancer Center

Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

07/27

CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL

Active, not recruiting

121

Europe, Canada, US

CTL019

Novartis Pharmaceuticals, Children's Oncology Group

B-Cell Acute Lymphoblastic Leukemia

10/27

NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting

1/2

Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16

St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach

Hemophagocytic Lymphohistiocytosis

08/25

08/26

CAR-20/19-T, NCT04049383: Cells in Patients With Relapsed/Refractory B Cell ALL

Suspended

CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells

Medical College of Wisconsin, Children's Hospital and Health System Foundation, Wisconsin

06/25

06/26

NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available

N/A

Canada, US, RoW

CTL019, tisagenlecleucel, Kymriah

Novartis Pharmaceuticals

Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)

MA, Wen Wee

eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting

250

Europe, Canada, Japan, US, RoW

zenocutuzumab (MCLA-128), bispecific, MCLA-128

Partner Therapeutics, Inc.

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

12/26

NCT04390243: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Terminated

Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818

Academic and Community Cancer Research United, National Cancer Institute (NCI)

Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

11/23

Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting

350

Europe, Canada, US

Actuate Therapeutics Inc., Actuate Therapeutics Inc

01/25

01/26

ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting

122

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080

Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.

12/24

12/26

NCT03337087: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active, not recruiting

1/2

Academic and Community Cancer Research United, National Cancer Institute (NCI)

03/21

08/25

ELU-FRÎ±-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated

1/2

ELU001, FA-CDC

Elucida Oncology

06/24

COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Active, not recruiting

1/2

Europe, Canada, US, RoW

TAK-280

Takeda, Takeda Development Center Americas, Inc.

Unresectable Locally Advanced or Metastatic Cancer

06/25

Recruiting

1/2

358

US, RoW

GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), ENHERTU®, pembrolizumab, KEYTRUDA®

GI Innovation, Inc., Merck Sharp & Dohme LLC

11/25

04/27

NCT06608940: BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Not yet recruiting

1/2

BC3402, Durvalumab, Tremelimumab

Case Comprehensive Cancer Center

Hepato Cellular Carcinoma (HCC)

01/27

01/28

KEYNOTE-E06, NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

	Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
	Sep 2021 - Sep 2021: Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO

Terminated

Oraxol, oral HM30181A + oral paclitaxel, Pembrolizumab, Keytruda

Athenex, Inc., Merck Sharp & Dohme LLC

Solid Tumor

05/23

12 3 4 5 6 7 8 9 10 »

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites